BR0317749A - Composto, composição farmacêutica, e, uso de um composto - Google Patents

Composto, composição farmacêutica, e, uso de um composto

Info

Publication number
BR0317749A
BR0317749A BR0317749-1A BR0317749A BR0317749A BR 0317749 A BR0317749 A BR 0317749A BR 0317749 A BR0317749 A BR 0317749A BR 0317749 A BR0317749 A BR 0317749A
Authority
BR
Brazil
Prior art keywords
compounds
compound
hiv
aids
inhibitors
Prior art date
Application number
BR0317749-1A
Other languages
English (en)
Inventor
Benedetta Crescenzi
Olaf Kinzel
Ester Muraglia
Federica Orvieto
Giovanna Pescatore
Michael Rowley
Viscenzo Summa
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Publication of BR0317749A publication Critical patent/BR0317749A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

"COMPOSTO, COMPOSIçãO FARMACêUTICA, E, USO DE UM COMPOSTO". As tetraidro-4H-pirido¢1,2-A!pirimidinas e compostos relacionados da Fórmula (I): são descritos como inibidores da HIV integrase e inibidores da replicação do HIV, em que n é um número inteiro igual a zero, 1 ou 2, e R¬ 1¬, R¬ 3¬, R¬ 4¬, R~ 12¬ e R~ 14~ são aqui definidos. Estes compostos são úteis na prevenção e tratamento de infecção pelo HIV e na prevenção, retardamento no início e tratamento da AIDS. Os compostos são utilizados contra a infecção pelo HIV e AIDS como compostos por si ou na forma de sais farmaceuticamente aceitáveis. Os compostos e seus sais podem ser utilizados como ingredientes em composições farmacêuticas, opcionalmente em combinação com outros antivirais, imunomoduladores, antibióticos ou vacinas.
BR0317749-1A 2002-12-27 2003-12-18 Composto, composição farmacêutica, e, uso de um composto BR0317749A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43683002P 2002-12-27 2002-12-27
US52877603P 2003-12-12 2003-12-12
PCT/GB2003/005543 WO2004058757A1 (en) 2002-12-27 2003-12-18 Tetrahydro-4h-pyrido[1,2-a]pyrimidines and related compounds useful as hiv integrase inhibitors

Publications (1)

Publication Number Publication Date
BR0317749A true BR0317749A (pt) 2005-11-22

Family

ID=32685467

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0317749-1A BR0317749A (pt) 2002-12-27 2003-12-18 Composto, composição farmacêutica, e, uso de um composto

Country Status (20)

Country Link
US (2) US7414045B2 (pt)
EP (1) EP1578748B1 (pt)
JP (1) JP4733986B2 (pt)
KR (1) KR20050087865A (pt)
CN (1) CN100343253C (pt)
AT (1) ATE481401T1 (pt)
AU (2) AU2003292437A1 (pt)
BR (1) BR0317749A (pt)
CA (1) CA2509554C (pt)
DE (1) DE60334248D1 (pt)
EC (1) ECSP055890A (pt)
HR (1) HRP20050593A2 (pt)
IS (1) IS7892A (pt)
MA (1) MA27583A1 (pt)
MX (1) MXPA05007010A (pt)
NO (1) NO20053624L (pt)
NZ (1) NZ540729A (pt)
PL (1) PL377354A1 (pt)
RU (1) RU2329265C2 (pt)
WO (2) WO2004058756A1 (pt)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135467B2 (en) * 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2005041664A1 (en) 2003-10-20 2005-05-12 Merck & Co., Inc. Hydroxy pyridopyrrolopyrazine dione compounds useful as hiv integrase inhibitors
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares
TW200526635A (en) * 2003-12-22 2005-08-16 Shionogi & Co Hydroxypyrimidinone derivative having HIV integrase inhibitory activity
US7273859B2 (en) 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
US7115601B2 (en) 2004-05-18 2006-10-03 Bristol-Myers Squibb Company HIV integrase inhibitors
US7176196B2 (en) * 2004-05-28 2007-02-13 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7173022B2 (en) 2004-05-28 2007-02-06 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7157447B2 (en) 2004-05-28 2007-01-02 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
US7192948B2 (en) * 2004-05-28 2007-03-20 Bristol-Myers Squibb Company Bicyclic heterocycles as HIV integrase inhibitors
WO2006060225A2 (en) * 2004-11-23 2006-06-08 Merck & Co., Inc. Process for asymmetric synthesis of hexahydropyrimido[1,2-a] azepine-2-carboxamides and related compounds
UA87884C2 (uk) * 2004-12-03 2009-08-25 Мерк Энд Ко., Инк. Безводна кристалічна калієва сіль інгібітора віл-інтегрази
CA2588466A1 (en) * 2004-12-03 2006-06-08 Merck & Co., Inc. Use of atazanavir for improving the pharmacokinetics of drugs metabolized by ugt1a1
ES2727577T3 (es) * 2004-12-03 2019-10-17 Merck Sharp & Dohme Composición farmacéutica que contiene un agente antinucleante
JP5228488B2 (ja) * 2004-12-03 2013-07-03 メルク・シャープ・アンド・ドーム・コーポレーション 放出速度調節組成物を含有しているカルボキサミドhivインテグラーゼ阻害薬の医薬配合物
EP1852434B1 (en) * 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
EP1866313A1 (en) * 2005-03-31 2007-12-19 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Hiv integrase inhibitors
DK3372281T3 (da) * 2005-04-28 2021-09-27 Viiv Healthcare Co Polycyklisk carbamoylpyridon-derivat med HIV-integrase-hæmmende aktivitet
EP1896448A1 (en) 2005-06-30 2008-03-12 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
US7494984B2 (en) * 2005-08-31 2009-02-24 Bristol-Myers Squibb Company Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors
CA2622639C (en) * 2005-10-04 2012-01-03 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. Hiv integrase inhibitors
JP2009513640A (ja) * 2005-10-27 2009-04-02 メルク エンド カムパニー インコーポレーテッド Hivインテグラーゼインヒビター
BRPI0617842A2 (pt) 2005-10-27 2011-08-09 Shionogi & Co composto ou um sal farmaceuticamente aceitável ou um solvato do mesmo, e, composição farmacêutica
WO2007059125A2 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors
WO2007058646A1 (en) * 2005-11-15 2007-05-24 Bristol-Myers Squibb Company Hiv integrase inhibitors: cyclic pyrimidinone compounds
US7902182B2 (en) * 2005-11-16 2011-03-08 Bristol-Myers Squibb Company HIV integrase inhibitors
US8039458B2 (en) * 2005-11-17 2011-10-18 Bristol-Myers Squibb Company HIV integrase inhibitors
WO2007064316A1 (en) * 2005-11-30 2007-06-07 Bristol-Myers Squibb Company Bicyclic heterocycles as hiv integrase inhibitors
US20070129379A1 (en) * 2005-12-01 2007-06-07 Bristol-Myers Squibb Company Hiv integrase inhibitors
US20090136570A1 (en) * 2006-01-20 2009-05-28 Bhagwant Rege Taste-Masked Tablets and Granules
US7897593B2 (en) 2006-05-30 2011-03-01 Bristol-Myers Squibb Company HIV integrase inhibitors
US7893055B2 (en) * 2006-06-28 2011-02-22 Bristol-Myers Squibb Company HIV integrase inhibitors
US7763630B2 (en) * 2007-06-06 2010-07-27 Bristol-Myers Squibb Company HIV integrase inhibitors
US8129398B2 (en) * 2008-03-19 2012-03-06 Bristol-Myers Squibb Company HIV integrase inhibitors
AU2009302663B2 (en) * 2008-10-06 2012-11-08 Merck Sharp & Dohme Corp. HIV integrase inhibitors
JP5086478B2 (ja) * 2008-12-11 2012-11-28 塩野義製薬株式会社 カルバモイルピリドンhivインテグラーゼ阻害剤及びそれらの中間体の合成
US8143244B2 (en) * 2009-02-26 2012-03-27 Bristol-Myers Squibb Company Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors
SG10201403149YA (en) * 2009-07-02 2014-08-28 Sanofi Sa Novel 1,2,3,4-tetrahydro-pyrimido(1,2-a)pyrimidin-6-one derivatives, preparation thereof and pharmaceutical use thereof
JP5624148B2 (ja) 2009-10-13 2014-11-12 エランコ・アニマル・ヘルス・アイルランド・リミテッド 大環状インテグラーゼ阻害剤
US8383639B2 (en) 2009-10-15 2013-02-26 Bristol-Myers Squibb Company HIV integrase inhibitors
BR112012009857A8 (pt) 2009-10-26 2023-04-11 Merck Sharp & Dohme Composições farmacêuticas sólidas contendo um inibidor de integrase
CN102958935B (zh) 2010-04-02 2015-12-09 爱尔兰詹森科学公司 大环整合酶抑制剂
UA112517C2 (uk) * 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US9949979B2 (en) 2011-12-15 2018-04-24 Novartis Ag Use of inhibitors of the activity or function of PI3K
WO2014099586A1 (en) 2012-12-17 2014-06-26 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
WO2014172188A2 (en) 2013-04-16 2014-10-23 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9643982B2 (en) 2013-05-17 2017-05-09 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
WO2014200880A1 (en) 2013-06-13 2014-12-18 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
MA38922A3 (fr) 2013-09-27 2018-11-30 Merck Sharp & Dohme Dérivés de quinolizine substitués utiles en tant qu'inhibiteurs de l'integrase du vih
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
US10548910B2 (en) 2015-11-17 2020-02-04 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as HIV integrase inhibitors
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
WO2017113288A1 (en) 2015-12-31 2017-07-06 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as hiv integrase inhibitors
JOP20190130A1 (ar) 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
WO2018102634A1 (en) 2016-12-02 2018-06-07 Merck Sharp & Dohme Corp. Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018140368A1 (en) 2017-01-26 2018-08-02 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as hiv integrase inhibitors
EA202092923A1 (ru) 2018-05-31 2021-04-09 Сионоги Энд Ко., Лтд. Полициклическое производное пиридона
PE20210477A1 (es) 2018-05-31 2021-03-11 Shionogi & Co Derivado policiclico de carbamoilpiridona

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262055B1 (en) 1998-06-03 2001-07-17 Merck & Co., Inc. HIV integrase inhibitors
US6306891B1 (en) 1998-06-03 2001-10-23 Merck & Co., Inc. HIV integrase inhibitors
US6380249B1 (en) 1998-06-03 2002-04-30 Merck & Co., Inc. HIV integrase inhibitors
JP2003503386A (ja) 1999-06-25 2003-01-28 メルク エンド カムパニー インコーポレーテッド 1−(芳香族またはヘテロ芳香族置換)−3−(ヘテロ芳香族置換)−1,3−プロパンジオン類およびそれの使用
WO2001094351A1 (en) * 2000-06-07 2001-12-13 Vertex Pharmaceuticals Incorporated Caspase inhibitors and uses thereof
GB0017676D0 (en) 2000-07-19 2000-09-06 Angeletti P Ist Richerche Bio Inhibitors of viral polymerase
CA2321348A1 (en) * 2000-09-27 2002-03-27 Blaise Magloire N'zemba Aromatic derivatives with hiv integrase inhibitory properties
AU2002230392A1 (en) 2000-10-12 2002-05-15 Merck & Co., Inc. AZA-and polyaza-naphthalenyl ketones useful as HIV integrase inhibitors
ATE345129T1 (de) 2000-10-12 2006-12-15 Merck & Co Inc Aza- und polyaza-naphthalenylcarbonsäureamide als hiv-integrase-hemmer
WO2002030426A1 (en) 2000-10-12 2002-04-18 Merck & Co., Inc. Aza- and polyaza-naphthalenyl-carboxamides useful as hiv integrase inhibitors
YU27903A (sh) 2000-10-12 2006-05-25 Merck & Co. Inc. Aza- i poliaza-naftalenil karboksamidi korisni kao inhibitori hiv-integraze
ES2383262T3 (es) 2001-08-10 2012-06-19 Shionogi & Co., Ltd. Agente antiviral
DK1441735T3 (da) 2001-10-26 2006-06-12 Angeletti P Ist Richerche Bio N-substituerede hydroxypyrimidinon-carboxamid-inhibitorer af HIV-integrase
ES2281565T3 (es) 2001-10-26 2007-10-01 Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.P.A. Inhibidores de la integrasa de vih de tipo dihidroxipirimidina carboxamida.
ATE370948T1 (de) 2002-01-17 2007-09-15 Merck & Co Inc Hydroxynaphthyridinoncarbonsäureamide, die sich als inhibitoren der hiv-integrase eignen
US7109186B2 (en) 2002-07-09 2006-09-19 Bristol-Myers Squibb Company HIV integrase inhibitors
US7135467B2 (en) 2003-01-13 2006-11-14 Bristol-Myers Squibb Company HIV integrase inhibitors
US7037908B2 (en) 2003-04-24 2006-05-02 Bristol-Myers Squibb Company HIV integrase inhibitors
AR046938A1 (es) * 2003-12-12 2006-01-04 Merck & Co Inc Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares

Also Published As

Publication number Publication date
CA2509554A1 (en) 2004-07-15
RU2329265C2 (ru) 2008-07-20
ATE481401T1 (de) 2010-10-15
US7414045B2 (en) 2008-08-19
US20080176869A1 (en) 2008-07-24
EP1578748B1 (en) 2010-09-15
JP2006513200A (ja) 2006-04-20
AU2003292436B2 (en) 2009-07-30
AU2003292437A1 (en) 2004-07-22
NZ540729A (en) 2008-03-28
US7968553B2 (en) 2011-06-28
DE60334248D1 (de) 2010-10-28
EP1578748A1 (en) 2005-09-28
MA27583A1 (fr) 2005-10-03
WO2004058756A1 (en) 2004-07-15
NO20053624L (no) 2005-09-26
AU2003292436A1 (en) 2004-07-22
PL377354A1 (pl) 2006-01-23
MXPA05007010A (es) 2005-08-18
RU2005123807A (ru) 2006-01-20
WO2004058757A1 (en) 2004-07-15
JP4733986B2 (ja) 2011-07-27
HRP20050593A2 (en) 2006-03-31
CN1753892A (zh) 2006-03-29
KR20050087865A (ko) 2005-08-31
CA2509554C (en) 2011-02-01
US20060046985A1 (en) 2006-03-02
IS7892A (is) 2005-06-13
NO20053624D0 (no) 2005-07-26
ECSP055890A (es) 2005-09-20
CN100343253C (zh) 2007-10-17

Similar Documents

Publication Publication Date Title
BR0317749A (pt) Composto, composição farmacêutica, e, uso de um composto
NO2020026I1 (no) Raltegravir eller et farmasøytisk akseptabelt salt derav, spesielt kaliumsaltet
DE60218511D1 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
WO2005120516A3 (en) Hiv integrase inhibitors
WO2005086700A3 (en) Hiv integrase inhibitors
WO2007146230A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2004024078A3 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
WO2008054605A3 (en) Non-nucleoside reverse transcriptase inhibitors
ATE517899T1 (de) Hiv-integrasehemmer
WO2007050510A3 (en) Hiv integrase inhibitors
WO2005115147A3 (en) Hiv reverse transcriptase inhibitors
WO2007002481A3 (en) Non-nucleoside reverse transcriptase inhibitors
WO2007002368A3 (en) Non-nucleoside reverse transcriptase inhibitors

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7AE 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2144 DE 07/02/2012.